Nitta Gelatin India Ltd
Incorporated in 1975, Nitta Gelatin India Ltd manufactures and sells ossein, gelatin, and collagen peptide[1]
- Market Cap ₹ 699 Cr.
- Current Price ₹ 770
- High / Low ₹ 1,184 / 745
- Stock P/E 9.56
- Book Value ₹ 416
- Dividend Yield 0.78 %
- ROCE 35.2 %
- ROE 27.0 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 89.2% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 25.3%
Cons
- The company has delivered a poor sales growth of 11.9% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
303 | 287 | 354 | 357 | 356 | 342 | 303 | 342 | 396 | 506 | 565 | 533 | 534 | |
260 | 271 | 330 | 321 | 320 | 313 | 273 | 306 | 351 | 442 | 452 | 409 | 427 | |
Operating Profit | 43 | 16 | 24 | 36 | 36 | 29 | 30 | 36 | 45 | 64 | 114 | 123 | 106 |
OPM % | 14% | 5% | 7% | 10% | 10% | 8% | 10% | 10% | 11% | 13% | 20% | 23% | 20% |
2 | 0 | 2 | 2 | 9 | 5 | 1 | 2 | 1 | 5 | 4 | 11 | 13 | |
Interest | 9 | 8 | 10 | 8 | 7 | 7 | 9 | 8 | 6 | 5 | 4 | 3 | 2 |
Depreciation | 16 | 17 | 14 | 13 | 14 | 15 | 15 | 16 | 16 | 14 | 14 | 15 | 15 |
Profit before tax | 20 | -9 | 1 | 18 | 24 | 12 | 7 | 13 | 25 | 49 | 99 | 116 | 102 |
Tax % | 55% | -23% | 358% | 53% | 49% | 61% | 33% | 8% | 29% | 29% | 25% | 28% | |
11 | -7 | -4 | 9 | 12 | 5 | 5 | 12 | 18 | 35 | 74 | 84 | 74 | |
EPS in Rs | 9.59 | -6.71 | -1.56 | 11.82 | 15.61 | 4.90 | 3.82 | 12.38 | 19.15 | 36.26 | 77.44 | 91.02 | 81.17 |
Dividend Payout % | 31% | 0% | -64% | 21% | 16% | 51% | 39% | 20% | 16% | 11% | 10% | 7% |
Compounded Sales Growth | |
---|---|
10 Years: | 6% |
5 Years: | 12% |
3 Years: | 10% |
TTM: | -4% |
Compounded Profit Growth | |
---|---|
10 Years: | 32% |
5 Years: | 89% |
3 Years: | 68% |
TTM: | -19% |
Stock Price CAGR | |
---|---|
10 Years: | 16% |
5 Years: | 44% |
3 Years: | 49% |
1 Year: | -14% |
Return on Equity | |
---|---|
10 Years: | 14% |
5 Years: | 20% |
3 Years: | 25% |
Last Year: | 27% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
Reserves | 105 | 100 | 99 | 105 | 124 | 139 | 141 | 144 | 164 | 192 | 259 | 334 | 369 |
57 | 68 | 66 | 92 | 109 | 104 | 108 | 84 | 80 | 86 | 39 | 14 | 18 | |
52 | 49 | 49 | 50 | 59 | 54 | 55 | 57 | 53 | 58 | 60 | 65 | 63 | |
Total Liabilities | 222 | 226 | 223 | 256 | 301 | 306 | 313 | 294 | 306 | 345 | 367 | 423 | 458 |
117 | 125 | 118 | 120 | 110 | 113 | 130 | 121 | 113 | 107 | 114 | 114 | 111 | |
CWIP | 9 | 9 | 9 | 9 | 13 | 10 | 4 | 4 | 2 | 7 | 7 | 8 | 9 |
Investments | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 12 |
96 | 92 | 96 | 127 | 177 | 182 | 179 | 169 | 191 | 230 | 246 | 300 | 326 | |
Total Assets | 222 | 226 | 223 | 256 | 301 | 306 | 313 | 294 | 306 | 345 | 367 | 423 | 458 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
17 | 24 | 20 | 20 | 11 | 27 | 22 | 40 | 19 | 17 | 101 | 94 | |
-13 | -24 | -8 | -14 | -3 | -7 | -14 | -10 | -7 | -14 | -18 | -54 | |
-3 | 0 | -12 | 18 | -5 | -20 | -7 | -33 | -12 | -2 | -55 | -36 | |
Net Cash Flow | 1 | -1 | 0 | 25 | 3 | -0 | 1 | -3 | -0 | 1 | 28 | 4 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 31 | 28 | 23 | 21 | 54 | 66 | 76 | 37 | 58 | 64 | 57 | 58 |
Inventory Days | 140 | 131 | 100 | 114 | 144 | 153 | 191 | 205 | 161 | 136 | 126 | 156 |
Days Payable | 58 | 72 | 51 | 42 | 48 | 53 | 59 | 49 | 43 | 28 | 39 | 44 |
Cash Conversion Cycle | 113 | 87 | 72 | 93 | 150 | 165 | 209 | 193 | 176 | 172 | 144 | 170 |
Working Capital Days | 66 | 62 | 54 | 58 | 97 | 94 | 108 | 78 | 107 | 113 | 90 | 97 |
ROCE % | 17% | -0% | 6% | 13% | 14% | 7% | 6% | 9% | 12% | 20% | 33% | 35% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 13 Nov
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 Nov - Copies of Newspaper Advertisements published in English and Malayalam Newspapers, pertaining to the Un-audited financial results of the Company for the Quarter and Half year …
-
Board Meeting Outcome for Outcome Of Board Meeting- Quarterly And Half Yearly Financial Results For The Period Ended 30Th September 2024
8 Nov - Un-audited financial results for Q2 and H1 2024.
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
29 Oct - Intimation of loss of share certificates and issuance of duplicates.
-
Board Meeting Intimation for Considering And Approving Inter Alia The Un-Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended 30Th September 2024
25 Oct - Board meeting scheduled for financial results approval.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
NGIL, a joint venture between the Kerala State Industrial Development Corporation (32% shareholding) and Osaka-based NGI (43% stake), manufactures gelatin, ossein, limed ossein, and DCP from processed animal bones. It also produces collagen peptide-based consumer products for the pharmaceutical and healthcare industries.